MX2022002537A - Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas. - Google Patents

Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas.

Info

Publication number
MX2022002537A
MX2022002537A MX2022002537A MX2022002537A MX2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A
Authority
MX
Mexico
Prior art keywords
bacterial infections
treating bacterial
beta
orally administered
avibactam
Prior art date
Application number
MX2022002537A
Other languages
English (en)
Inventor
Joaquim Trias
Carole Sable
Andrew Nicholls
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of MX2022002537A publication Critical patent/MX2022002537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones farmacéuticas comprenden un antibiótico de ß-lactama y un derivado de avibactam y métodos para tratar infecciones bacterianas que utilizan las composiciones farmacéuticas. Las composiciones farmacéuticas pueden formularse para su administración oral y después de la administración oral proporcionar una cantidad terapéuticamente efectiva de antibiótico ß-lactama y avibactam en la circulación sistémica de un paciente. Las composiciones farmacéuticas orales pueden ser métodos, pueden utilizarse para tratar infecciones provocadas por bacterias que producen enzimas ß-lactama.
MX2022002537A 2019-08-29 2020-08-27 Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas. MX2022002537A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893612P 2019-08-29 2019-08-29
US201962953852P 2019-12-26 2019-12-26
PCT/US2020/048119 WO2021041616A1 (en) 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Publications (1)

Publication Number Publication Date
MX2022002537A true MX2022002537A (es) 2022-03-22

Family

ID=72433031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002537A MX2022002537A (es) 2019-08-29 2020-08-27 Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas.

Country Status (11)

Country Link
US (2) US20210060033A1 (es)
EP (1) EP4021443A1 (es)
JP (1) JP2022545291A (es)
KR (1) KR20220054364A (es)
CN (1) CN114302725A (es)
AU (2) AU2020337449A1 (es)
BR (1) BR112022001344A2 (es)
CA (1) CA3152300C (es)
IL (1) IL290260A (es)
MX (1) MX2022002537A (es)
WO (1) WO2021041616A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512793A (ja) * 2021-04-05 2024-03-19 キューペックス バイオファーマ， インコーポレイテッド セフチブテン投与レジメン
EP4362950A1 (en) * 2021-07-01 2024-05-08 Qpex Biopharma, Inc. Crystalline forms of ceftibuten
CN115448920A (zh) * 2022-10-14 2022-12-09 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116327764B (zh) * 2023-04-06 2024-04-12 浙江医药股份有限公司新昌制药厂 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) * 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
AU2018345321B2 (en) 2017-10-02 2021-05-20 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof

Also Published As

Publication number Publication date
AU2020337449A1 (en) 2022-03-03
BR112022001344A2 (pt) 2022-06-07
EP4021443A1 (en) 2022-07-06
JP2022545291A (ja) 2022-10-26
IL290260A (en) 2022-04-01
US20210060033A1 (en) 2021-03-04
US20230210863A1 (en) 2023-07-06
CA3152300C (en) 2024-04-30
AU2024201877A1 (en) 2024-04-11
CN114302725A (zh) 2022-04-08
KR20220054364A (ko) 2022-05-02
CA3152300A1 (en) 2021-03-04
WO2021041616A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2022002537A (es) Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas.
Legent et al. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis
Levi et al. Oral infections and antibiotic therapy
DK1506214T3 (da) 6-11 bicykliske ketolidderivater
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
NZ552047A (en) Method of treatment of endobronchial infections
Peedikayil Antibiotics in odontogenic infections-an update
CR20200148A (es) Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
SA518390825B1 (ar) مضاد حيوي جديد فعال من أمينو جلايكوسيد للبكتيريا المضادة لعقاقير متعددة
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2021000868A (es) Uso de especies gram negativas para tratar la dermatitis atopica.
DE69723864D1 (en) Ethyliden-derivate tricyclyscher carbapenems
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
CN107320466A (zh) 厚朴酚在制备ndm‑1酶抑制剂中的医用用途
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
AR120862A1 (es) Combinaciones de amoxicilina y derivados de avibactam administrados oralmente para tratar infecciones micobacterianas
UY28340A1 (es) Profármaco inhibidor de beta-lactamasa
MX2022011821A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
KR20140056179A (ko) 치과 감염 치료를 위한 세크니다졸의 사용
NZ804243A (en) Lactivicin compounds, their preparation and use as antibacterial agents